Letter to John Dankovich aka Jonathan Cross
Cease and desist letter sent to John Dankovitch aka Jonathan Cross.
Groundbreaking Leap Forward in THCT's New Business Plan
THC Therapeutics has entered into an agreement to secure up to $50 million in funding with Shefford Capital Partners for acquisitions in the cannabis, alternative therapies and modern health space.
THC Therapeutics Has Completed the dHydronator® Consumer Model Design
THCT has leveraged the extensive market research commissioned through Keyhole Research to redesign the dHydronator® for the consumer market.
THC Therapeutics is an audited, SEC reporting company. Visit our disclosures page to browse through our filings.
For detailed investor inquiries you can reach out to our Investor Relations firm via email or phone.
Public companies can be daunting to newcomers, read through our investors most commonly asked questions.